Research programme: severe acute respiratory syndrome-coronavirus PL protease inhibitors - Microbial Novoteqs
Latest Information Update: 28 Aug 2020
At a glance
- Originator Microbial Novoteqs
- Class Antivirals
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Severe acute respiratory syndrome in USA
- 11 Jul 2016 Early research in Severe acute respiratory syndrome in USA (unspecified route)
Development Overview
Introduction
Microbial Novoteqs is developing severe acute respiratory syndrome-coronavirus (SARS-CoV) PL protease inhibitors for the treatment of SARS. The company has received $US1.7 million in grants and additional subcontracts from the National Institutes of Health (NIH) to partly pursue high-throughput screening for inhibitors of viral agents that pose global health threats. According to the company pipeline, as of July 2016, development is at the early research (high-throughput screening) stage in the US.
As at August 2020, no recent reports of development had been identified for research development in Severe acute respiratory syndrome in USA.
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Antivirals
- Target Peptide hydrolase
- Mechanism of Action Peptide hydrolase inhibitors
-
WHO ATC code
J05A-E (Protease inhibitors)
-
EPhMRA code
J5B5 (Respiratory antivirals excluding influenza products)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Severe acute respiratory syndrome | - | - | No development reported (Research) | USA | unspecified / unspecified | Microbial Novoteqs | 28 Aug 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Microbial Novoteqs | Originator | USA |
| Microbial Novoteqs | Owner | USA |
| National Institutes of Health (USA) | Funder | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Aug 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Severe acute respiratory syndrome in USA Updated 28 Aug 2020 |
| 11 Jul 2016 | Phase Change | Early research in Severe acute respiratory syndrome in USA (unspecified route) Updated 11 Jul 2016 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG